1 September 2015 - The September 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule inclides the following new and revised listings:

• Amino acid formula with vitamins and minerals without lysine and low in tryptophan (XYLS Low Try Maxamum) - new formulation
• Febuxostat (Adenuric) - new medicine
• Follitropin alfa with lutropin alfa (Pergoveris) - new combination product
• Lisdixamphetamine dimesylate (Vyvanse) - new medicine
• Lutropin alfa (Luveris) - new listing
• Posaconazole (Noxafil) - new formulation
• Pembrolizumab (Keytruda) - new listing
• Secukinumab (Cosentyx) - new listing
• Sunitinib maleate (Sutent) - new strength

The Schedule also includes the delisting of a number of recent listings:

• Apomorphine hydrochloride (Apomine PFS)
• Glucose indicator (Lifeline Attest)
• Glucose indicator (Easymate II)
• Rivastigmine hydrogen tartrate (Exelon)
• Telaprevir (Incivo)

For more details, go to: http://www.pbs.gov.au/publication/schedule/2015/09/2015-09-01-general-schedule-soc.pdf